Evidence map›Paper›PMID 26798768›Full record

ArticleCardiovascular pharmacology: open access2015

AMP-Activated Protein Kinase Signalling in Cancer and Cardiac Hypertrophy.

Yulia Lipovka, John P Konhilas

Open access · hybridAbstract read
In one paragraph

Article in Cardiovascular pharmacology: open access, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Engineering Nanoparticles and Bioscaffolds for Targeted microRNA Delivery in Cardiovascular Regeneration-A Comprehensive Review.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. The role of ectopic adipose tissue: benefit or deleterious overflow?European journal of clinical nutrition · 2021
    Review
  8. Article
  9. Review
  10. Chemical diversity and pharmacological significance of the secondary metabolites of nutmeg (Phytochemistry reviews : proceedings of the Phytochemical Society of Europe · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Yulia LipovkaDepartment of Physiology, University of Arizona, Sarver Molecular Cardiovascular Research Program, USA.
John P KonhilasDepartment of Physiology, University of Arizona, Sarver Molecular Cardiovascular Research Program, USA.
University of Arizona · US

Funding

Impact of AMP-activated kinase on sex differences in hypertrophic cardiomyopathyR01HL098256 · NHLBI · UNIVERSITY OF ARIZONA · PI KONHILAS, JOHN P · 2010 to 2014
$1.9M
Metabolism, Skeletal Muscle, Cardiac Disease, ExerciseK01AR052840 · NIAMS · UNIVERSITY OF COLORADO · PI KONHILAS, JOHN P · 2006 to 2010
$600k
Impact of AMP-activated kinase on sex differences in hypertrophic cardiomyopathyK02HL105799 · NHLBI · UNIVERSITY OF ARIZONA · PI KONHILAS, JOHN P · 2011 to 2015
$516k
NHLBI NIH HHS K02 HL105799NHLBI NIH HHS R01 HL098256NIAMS NIH HHS K01 AR052840
6 · The paper itself

Abstract

The AMP-protein kinase (AMPK) pathway is very versatile as it regulates cellular energetic homeostasis in many different tissue types. An appreciation for the importance of AMPK signalling and regulation in cardiovascular and tumor biology is increasing. Recently, a link has been established between anti-cancer therapy and susceptibility to cardiac disease. It has been shown that some anti-cancer drugs lead to an increased risk of cardiac disease, underlined by de-regulation of AMPK signalling. This review explores the AMPK signalling axis in both cardiac and tumor metabolism. We then examine off-target AMPK inhibition by cancer drugs and how this may translate into increased risk of cardiovascular disease. Finally, we discuss the implication of deregulated AMPK signalling during different stages of cardiac hypertrophy. Better understanding of the molecular pathways behind pathological processes will lead to the development of more effective therapeutics for cancer and cardiovascular diseases.

Indexed as

AMP-activated protein kinaseCancerCardiotoxicityHypertrophyMetabolism

Identifiers

PMID26798768
PMCPMC4718578
OpenAlexW1249898541

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.